Novo Nordisk’s oral version of Wegovy attracted over 10,000 people to a waiting list at UK pharmacy Chemist4U. This high interest signals strong demand for a tablet alternative to weekly injections.
The Medicines and Healthcare products Regulatory Agency is currently reviewing the higher-dose semaglutide tablet. A regulatory decision is anticipated in late 2026.
Approximately 75% of those on the waitlist have not previously used weight-loss injections. This suggests the pill format will expand the market to new users who prefer to avoid needles. Other pharmacies are also preparing for significant public interest.